Some of Thursday's midday movers:» Read More
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.
Plus, should I own Pfizer?
The Dow closed lower on Wednesday as nervous investors found it difficult to muster enthusiasm ahead of the Senate’s vote on a revamped $700 billion rescue plan.
Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.
Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.
The Dow tumbled on Monday as investors worried a $700 billion bailout for the financial sector may not resuscitate a slumping economy...
The Lightning Round is extended in this CNBC.com exclusive feature.
As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."
The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.
The Dow and S&P 500 fell over 4.5% today, while the Nasdaq composite dropped 3.6%, as concerns over the health of the financial sector intensified following the decision of Lehman Brothers to file for Chapter 11.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.
Cramer makes the call on viewers' favorite stocks.
John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.
One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.
A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.
Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.
In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).
When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.
Stocks finished higher in feather-light trading Wednesday, boosted by a rise in financials and energy stocks, as well as a better-than-expected durable-goods report.